



781 Chestnut Ridge Rd.
Morgantown, WV 26505 USA
Phone 800.848.0462
Fax 877.835.4329
Web mylan.com

1901 N. Roselle Road, Suite 450
Schaumburg, IL 60195
www.sagentpharma.com

Dear Valued Customer,

Sagent Pharmaceuticals, Inc. (“Sagent”) and Mylan Institutional, Inc. (“Mylan”) have entered into an agreement involving a select portfolio of products that were part of the previous Sagent-Strides/Agila Joint Venture. The Joint Venture was terminated effective April 10, 2017 and Sagent will transfer its existing inventory of the Sagent labeled products to Mylan effective no later than April 13, 2017. As a result of Mylan purchasing this inventory from Sagent, we would like to inform you of important upcoming changes to contracts, product orders, EDI transactions, payments and returns for these Sagent labeled products. After the Sagent inventory is depleted, Mylan plans to introduce the products in new Mylan labels manufactured by Agila, the same company that manufactured the Sagent labeled products.

The products Sagent will be removing from its commercial contracts are listed on Attachment 1. Mylan will begin selling currently available products immediately utilizing the existing Sagent labeler code.

Wholesalers:

Mylan will be submitting appropriate documentation, in the form of an offer letter or an amendment referencing or listing Mylan terms and conditions, to wholesalers it wishes to offer these products to. Please execute and return any such document prior to placing an order. If you have an active direct account with Mylan and you do not receive documentation from Mylan and you would like to receive an offer so that your company can continue to purchase these products, please contact your account manager or Customer relations at number listed below and Mylan will consider your request. Mylan will only sell product and pay fees, rebates and/or or penalties with regard to products it sells pursuant to written agreements it has entered specifically referencing these products.

Other Customers:

Mylan will be sending appropriate documentation, in the form of an offer letter or an amendment referencing or listing Mylan terms and conditions, to certain of its commercial customers (e.g. group purchasing organizations and integrated delivery networks) where Mylan wishes to offer one or more of these products. If you do not receive an offer from Mylan and you would like to receive an offer so that your company can purchase these products, please contact your account manager or Customer relations at number listed below and Mylan will consider your request. Mylan will only sell product and pay fees, rebates or penalties with regard to products it sells pursuant to its written agreements it has entered specifically referencing these products.

Sagent has or will be sending appropriate documentation to remove these products from its commercial contracts effective as of April 10, 2017.

Wholesaler Ordering:

On and after April 10, 2017, please continue ordering the Sagent labeled products set forth in Attachment 1 utilizing the Sagent NDC numbers set forth in Attachment 1 by placing orders with Mylan. As of April 10, 2017, if you have placed an order with Sagent for these products which has not yet been filled, please submit a new purchase order to Mylan for these products.

Wholesaler Chargebacks:

Mylan will begin processing chargebacks with regard to the products set forth in Attachment 1 effective as of April 10, 2017.

Below is Mylan contact information for your convenience:

Customer Relations Telephone: 1.800.848.0462
Customer Relations Facsimile: 1.877.835.4329
Accounts Receivable Facsimile: 1.304.285.6434

EDI: Qualifier/ID 12/8152821201
Mail: Mylan Institutional Inc.
P.O. Box 4310
Morgantown, West Virginia 26505

EDI Transactions:

Additionally, Electronic Data Interchange (EDI) customers that have been an established trading partner with Mylan should send their product information by means of EDI transactions. These transactions include: **810-Invoice, 844-Chargebacks, 845-Global Bid Award, 849-Chargeback Reconciliation, 850-Purchase Order, and 856-Advance Shipment Notification**. The EDI transactions will be processed in a manner consistent with Mylan's EDI Specifications. EDI Documents will be traded under the **Test ISA Qualifier/ID '12/8152821201T'** and the **Production ISA Qualifier/ID '12/8152821201'** utilizing the communication protocol already in place for your existing Mylan Trading Partner relationship. EDI inquiries should be directed to the EDI department via email at Commerce@mylan.com and/or by telephone at **1.304.554.6485**.

For EDI customers currently sending EDI 852 (Product Activity Data) and 867 (Product Transfer and Resale Report) to Mylan, please begin transmitting this information for these products as of December 7, 2013.

Please note, Mylan is required to pass Pedigree in any state that it is mandated.

Payment:

Regarding invoicing, please remit payments for Sagent outstanding invoices to the address depicted on your invoice from Sagent. Please submit payments for Mylan invoices to the address depicted below.

Mylan Institutional
P.O. Box 7247-7323
Philadelphia, PA 19170-7323

Returns of Sagent labeled product set forth on Attachment 1:

Please be advised that expired and/or outdated product returns for the Sagent labeled products listed on Attachment 1 should be returned to Sagent so that the same can be handled or processed utilizing the Sagent Return Goods Policy. This will apply to all Sagent labeled products, regardless of when the products were purchased, and including products purchased from Mylan on and after April 10, 2017.

Mylan remains committed to providing quality and exceptional service, and it has remained our goal to make certain this transition is as seamless as possible. We kindly ask that this information be distributed to all appropriate departments within your organization; this includes providing a copy of this letter to respective Inventory Replenishment Buyers.

Please direct questions pertaining to this important customer notification to our Customer Relations Department at 1.800.848.0462. Thank you for your time involved; we truly value our business relationship and respectfully appreciate your continued support of our company.

Regards,

Don Bullock
Executive Vice President, Sales

Morgan Dillon
Manager, Mylan Institutional, Inc. Customer Relations

Attachment 1

NDC	Product	Currently Available Inventory for Purchase by Wholesalers from Mylan
25021-0817-10	Acetazolamide Sodium Injection (1pk, SDV, 500mg)	✓
25021-0301-02	Adenosine Injection (10pk, SDV, 2ml, 3mg/ml)	
25021-0301-04	Adenosine Injection (10pk, SDV, 4ml, 3mg/ml)	
25021-0307-20	Adenosine Injection (1pk, SDV, 20ml, 3mg/ml)	
25021-0307-30	Adenosine Injection (1pk, SDV, 30ml, 3mg/ml)	
25021-0307-66	Adenosine Injection NovaPlus (1pk, MDV, 20ml, 3mg/ml)	
25021-0307-67	Adenosine Injection NovaPlus (1pk, MDV, 30ml, 3mg/ml)	
25021-0112-10	Azithromycin Injection (10pk, SDV, 500mg)	✓
25021-0778-01	Granisetron HCl Injection Preservative Free (5pk, SDV, 1ml, 0.1mg/ml)	✓
25021-0778-66	Granisetron HCl Injection Preservative Free NovaPlus (5pk, SDV, 1ml, 0.1mg/ml)	✓
25021-0779-01	Granisetron HCl Injection Preservative Free (1pk, SDV, 1ml, 1mg/ml)	
25021-0781-04	Granisetron HCl Injection (1pk, MDV, 4ml, 1mg/ml)	✓
25021-0130-20	Levofloxacin Injection (1pk, SDV, 20ml, 25mg/ml)	✓
25021-0130-30	Levofloxacin Injection (1pk, SDV, 30ml, 25mg/ml)	✓
25021-0303-05	Metoprolol Tartrate Injection (10pk, SDV, 5ml, 1mg/ml)	✓
25021-0655-02	Midazolam HCl Injection Preservative-Free (10pk, SDV, 2ml, 1mg/ml)	
25021-0655-05	Midazolam HCl Injection Preservative-Free (10pk, SDV, 5ml, 1mg/ml)	
25021-0656-01	Midazolam HCl Injection Preservative-Free (10pk, SDV, 1ml, 5mg/ml)	
25021-0656-02	Midazolam HCl Injection Preservative-Free (10pk, SDV, 2ml, 5mg/ml)	
25021-0660-10	Midazolam HCl Injection (10pk, MDV, 10ml, 1mg/ml)	
25021-0661-05	Midazolam HCl Injection (10pk, MDV, 5ml, 5mg/ml)	
25021-0661-10	Midazolam HCl Injection (10pk, MDV, 10ml, 5mg/ml)	
25021-0652-30	Ropivacaine HCl Injection 0.5% (1pk, SDV, 30ml, 5mg/ml)	✓
25021-0652-31	Ropivacaine HCl Injection 0.5% (5pk, SDV, 30ml, 5mg/ml)	
25021-0653-20	Ropivacaine HCl Injection 1% (5pk, SDV, 20ml, 10mg/ml)	
25021-0654-20	Ropivacaine HCl Injection 0.75% (5pk, SDV, 20ml, 7.5mg/ml)	
25021-0671-20	Ropivacaine HCl Injection 0.2% (5pk, SDV, 20ml, 2mg/ml)	
25021-0703-60	Sumatriptan Succinate Injection (5pk, SDV, 0.5ml, 6mg/0.5ml)	✓
25021-0703-70	Sumatriptan Succinate Syringe (2pk, SYG, 0.5ml, 6mg/0.5ml)	